Publication | Closed Access

A phase 2, adaptive randomized, double-blind, placebo-controlled, multicenter, 52-week study of HM15211 in patients with biopsy-confirmed non-alcoholic steatohepatitis – Study design and rationale of HM-TRIA-201 study

Hepatology52-Week StudyClinical TrialsPathologyLiver DiseaseFatty Liver DiseasePhase 2Hm-tria-201 StudyMedicine